TerminatedPhase 2

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of RO6807952 in Type 2 Diabetic Patients Inadequately Controlled With Metformin Alone

Lead sponsor

Hoffmann-La Roche

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

Primary endpoint

•HbA1c, change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01516476

Org study IDBP27804

Timeline

Milestones

Study first posted2012-01-24estimated

Last update posted2016-11-02estimated

Study start2011-11 (month precision)

Primary completion2012-01actual (month precision)

Study completion2012-01actual (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Adult patients >/= 18 and </=70 years of age

•Diagnosis of diabetes mellitus, type 2 for at least 3 months

•Treated with a stable dose of metformin

•Hemoglobin A1c >/=7.0% and </=10.5% at screening

•Fasting plasma glucose </=240 mg/dL at screening

•Body mass index >/=27 kg/m2 and </=42 kg/m2 at screening

•Willing and able to maintain existing diet and exercise habits throughout the study

•C-peptide >1.5 ng/mL at screening

Exclusion criteria

•History of significant liver or kidney disease

•History of uncontrolled hypertension

•History of significant cardiovascular disease

•History of significant diabetic complications

•History of significant gastrointestinal conditions

•History of weight loss surgery or procedures involving the gastrointestinal tract

•History of chronic or acute pancreatitis

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Safety / tolerability / PK

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

Change in hemoglobin A1c (HA1c)

Time frame:Baseline and 12 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in fasting plasma glucose

Time frame:Baseline and 12 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Safety (incidence of adverse events)

Time frame:12 weeks

Treatment-emergent AEs (any)

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.